A Phase 1 interventional study of Ixekizumab and Boostrix® in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2. Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2.
Drug: Ixekizumab · Drug: Boostrix® · Drug: Pneumovax®23
Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
Drug: Boostrix® · Drug: Pneumovax®23
Administered by SQ injection
Also known as: LY2439821
Administered by IM injection
Also known as: Tetanus, diphtheria, acellular pertussis vaccine (Tdap)
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Administered by IM injection
Also known as: Pneumococcal polysaccharide vaccine
Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations
Responder to tetanus vaccine defined as a post-vaccination anti-tetanus antibody concentration of \>=1.0 (International Unit (IU) and a \>=1.5-fold increase (50% increase) from baseline if the pre-vaccination concentration is \<=1.0 at baseline OR a \>=2.5-fold increase (150% increase) from baseline if the pre-vaccination concentration is \> 1.0 IU at baseline. Responder to the pneumococcal vaccine is defined as a \>=2-fold increase (100% increase) from baseline in anti-pneumococcal antibody concentrations against \>50% of the 23 serotypes.
Time frame: Week 6
| Milestone | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 |
|---|---|---|
| Started | 41 | 43 |
| Received at least 1 dose of study drug | 41 | 42 |
| Completed | 38 | 39 |
| Not completed | 3 | 4 |
| Withdrew: Never treated | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
Responder to tetanus vaccine defined as a post-vaccination anti-tetanus antibody concentration of \>=1.0 (International Unit (IU) and a \>=1.5-fold increase (50% increase) from baseline if the pre-vaccination concentration is \<=1.0 at baseline OR a \>=2.5-fold increase (150% increase) from baseline if the pre-vaccination concentration is \> 1.0 IU at baseline. Responder to the pneumococcal vaccine is defined as a \>=2-fold increase (100% increase) from baseline in anti-pneumococcal antibody concentrations against \>50% of the 23 serotypes.
| percentage of participants | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 |
|---|---|---|
| Tetanus Vaccine Responders | 52.6 | 51.2 |
| Pneumococcal Vaccine Responders | 89.5 | 90.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab + Boostrix® + Pneumovax®23 | — | 0/41 (0%) | 1/41 (2.4%) |
| Boostrix® + Pneumovax®23 | — | 0/42 (0%) | 0/42 (0%) |
| Event | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 |
|---|---|---|
| Vulvovaginal candidiasisInfections and infestations | 1/19 | 0/18 |
| Age, Continuous(years) | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 | Total |
|---|---|---|---|
| Mean | 43.5 ± 12.2 | 39.5 ± 10.5 | 41.4 ± 11.5 |
| Gender(Participants) | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 | Total |
|---|---|---|---|
| Female | 19 | 19 | 38 |
| Male | 22 | 24 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 34 | 35 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 17 | 32 |
| White | 24 | 25 | 49 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ixekizumab + Boostrix® + Pneumovax®23 | Boostrix® + Pneumovax®23 | Total |
|---|---|---|---|
| United States | 41 | 43 | 84 |
The record gives a start of Sep 2015, a primary completion of Nov 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab